News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Investors Hold Their Breath for Gilead (GILD)'s Late-Stage Myelofibrosis Data



11/9/2016 5:49:22 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

One of these Gilead studies compares momelotinib head-to-head against Jakafi, another Jak inhibitor and the current standard of care in myelofibrosis marketed by Incyte (INCY) and Novartis (NVS) . The second study compares Gilead's momelotinib against best alternative care in patients previously treated with Jakafi.

Read at The Street.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES